COMP <GO>
ADPT vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Adaptive Biotechnologies Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ADPT 4
— ABBV 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $28.17 (-0.70%) • MKT CAP: $4.50B
roic
-12.50%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADPT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADPT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.20% | 70.20% | +4.00 | ADPT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -12.50% | 29.00% | -41.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.09% | 3.47% | -4.56 | ABBV | /fcf-yield <GO> |
| Operating Margin | -20.60% | 24.60% | -45.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -21.50% | 6.90% | -28.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 54.80% | 8.60% | +46.20 | ADPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.32 | 5.33 | +0.99 | ADPT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.6 | 65.1 | -7.50 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.15 | -0.14 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.0x | 113.1x | -87.10 | ADPT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.50B | $513.86B | -$509.36B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADPT REV | ABBV REV | ADPT GROSS % | ABBV GROSS % | ADPT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $277.0M | $61.16B | 74.2% | 70.2% | -$48.9M | $17.82B |
| FY 2024 | $179.0M | $56.33B | 59.7% | 70.0% | -$98.9M | $17.83B |
| FY 2023 | $170.3M | $54.32B | — | — | -$164.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADPT // BETA 1.01
ABBV // BETA 1.15